Webinar: The Future of Clinical Trial Monitoring
In the wake of COVID-19, adoption of decentralized clinical research is taking off as sponsors explore ways to maintain continuity for existing studies while looking…
Read More
Over 300 Clinical Studies Benefit from CluePoints’ COVID-19 Risk Management Support
Addressing COVID-19 Specific Regulatory Guidance and Ensuring Early Risk Detection King of Prussia, PA – August 4th, 2020: CluePoints, the premier provider of Risk-Based…
Read More
New Paper: From RBM to RBQM – The Future of Risk-Based Trial Management
A review of FDA marketing submissions between 2000 and 2012 revealed roughly one-third (32%) of all first-cycle review failures (16% of submissions overall) were driven…
Read More
CluePoints & DIA Webinar: How is the Industry Coping with the Move to Remote Monitoring?
On July 28, CluePoints is teaming up with DIA for a webinar to explore how the clinical research industry is coping with the move to…
Read More
RBQM Doesn’t have to be Complicated, Risky or Expensive: Q&A
On Wednesday, June 24, 2020, CluePoints delivered a webinar to demonstrate how using a combination of powerful analytics and comprehensive data visualization can be employed…
Read More
CluePoints Launches Powerful Business Intelligence Platform
Personalizing the Power of Statistical Analysis and Data Visualization King of Prussia, PA – June 26, 2020: CluePoints, the premier provider of Risk-Based Study Execution…
Read More
New Webinar: Risk-Based Quality Management Doesn’t have to be Complicated, Risky or Expensive!
Register Now for our June 24, 2020 Webinar:Risk Detection and Data Visualization Techniques that Actually Deliver on the Promise. Managing and mitigating risk, particularly in…
Read More
CluePoints Covid-19 Support Benefits Over 200 Clinical Studies Directly Affected by the Pandemic
RISK MANAGEMENT SOLUTION ADDRESSES FDA, EMA, PMDA & MHRA CORONAVIRUS ADVICE King of Prussia, PA – May 07, 2020: CluePoints, the premier provider of Risk-Based…
Read More
Events
Find out where we’re headed next.
Featured Whitepaper
ICH E6 (R2)
Summary
Paper
Created in conjunction with our peers at TUFTS Center for the Study of Drug Development, this paper provides insights on how companies are responding to ICH E6 (R2) and information on the key themes on adoption.
Featured Webinar
ICH E6 (R2)
Webinar
Series
This recorded webinar covers all of the frequently asked Questions about ICH E6 (R2), Risk-Based Study Execution (RBx) and what’s required from a people, process & technology standpoint.
We're Kind of a Big Deal.
2,500
Platform Users
350
Studies De-Risked
15,000
Issues Detected